Kenza Health Hub logoGet Started
1 May 2026Injectable drugsSource update: October 2024

Digoxin Injectable: Dosing and Precautions

Injectable digoxin guidance for supraventricular arrhythmias and heart failure, with a narrow therapeutic range.

Also searched as

Digoxin
Prescription under medical supervision

Source reviewed

October 2024

Guide category

Injectable drugs

Safety boundary

Prescription medicine information for clinician-guided use.

Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.

This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Cardiotonic.

Indications

  • Supraventricular arrhythmias such as fibrillation, flutter, and paroxysmal tachycardia.
  • Heart failure.

Forms and strengths, route of administration

  • 500 micrograms ampoule, 250 micrograms/ml in 2 ml, for slow IV injection or infusion in 5% glucose or 0.9% sodium chloride.

Dose

  • Adult loading dose: 500 to 1000 micrograms.
  • The loading dose can be administered either by intravenous infusion as a single dose over at least 2 hours or in divided doses by slow IV injections over at least 5 minutes.
  • Maintenance dose: change to oral treatment.
  • Reduce the dose by one half in older patients and in patients with renal impairment.

Contra-indications, adverse effects, precautions

Due to the narrow margin between therapeutic and toxic dose, patients should be kept under close surveillance.

It is essential to monitor heart rate in the initial stage of treatment.

  • Do not administer to patients with bradycardia, ill-defined arrhythmia, or coronary artery disease.
  • May cause in overdose gastrointestinal disturbances, blurred vision, headache, confusion, and conduction or rhythm disorders.
  • Do not combine with calcium, particularly by IV injection.
  • Monitor combination with amiodarone, macrolides, itraconazole, quinine, chloroquine, and potassium-depleting drugs.
  • If possible, monitor serum potassium in patients taking potassium-depleting drugs and serum creatinine in patients with renal impairment.
  • Pregnancy: no contra-indication.
  • Breast-feeding: no contra-indication.

Source

MSF Essential drugs practical guidelines (January 2026)

This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.

Rate this guide

Be the first to rate this guide.